BRIEF-BioCryst receives more funding for developing treatment for hemorrhagic fever virus diseases
July 05, 2016 at 07:55 AM EDT
* Funding represents an additional $5.5 million to BioCryst for development of BCX4430 as a treatment for hemorrhagic fever viruses